PMID- 37740111
OWN - NLM
STAT- MEDLINE
DCOM- 20231216
LR  - 20240227
IS  - 1179-2000 (Electronic)
IS  - 1177-1062 (Print)
IS  - 1177-1062 (Linking)
VI  - 27
IP  - 6
DP  - 2023 Nov
TI  - Cell Therapy of Severe Ischemia in People with Diabetic Foot Ulcers-Do We Have 
      Enough Evidence?
PG  - 673-683
LID - 10.1007/s40291-023-00667-w [doi]
AB  - This current opinion article critically evaluates the efficacy of autologous cell 
      therapy (ACT) for chronic limb-threatening ischemia (CLTI), especially in people 
      with diabetes who are not candidates for standard revascularization. This 
      treatment approach has been used in 'no-option' CLTI in the last two decades and 
      more than 1700 patients have received ACT worldwide. Here we analyze the level of 
      published evidence of ACT as well as our experience with this treatment method. 
      Many studies have shown that ACT is safe and an effective method for patients 
      with the most severe lower limb ischemia. However, some trials did not show any 
      benefit of ACT, and there is some heterogeneity in the types of injected cells, 
      route of administration and assessed endpoints. Nevertheless, we believe that ACT 
      plays an important role in a comprehensive treatment of patients with diabetic 
      foot and severe ischemia.
CI  - (c) 2023. The Author(s).
FAU - Dubsky, Michal
AU  - Dubsky M
AD  - Institute for Clinical and Experimental Medicine, Prague, Czech Republic. 
      mids@ikem.cz.
AD  - First Faculty of Medicine, Charles Universtiy, Prague, Czech Republic. 
      mids@ikem.cz.
FAU - Husakova, Jitka
AU  - Husakova J
AD  - Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
AD  - First Faculty of Medicine, Charles Universtiy, Prague, Czech Republic.
FAU - Sojakova, Dominika
AU  - Sojakova D
AD  - Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
AD  - First Faculty of Medicine, Charles Universtiy, Prague, Czech Republic.
FAU - Fejfarova, Vladimira
AU  - Fejfarova V
AD  - Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
FAU - Jude, Edward B
AU  - Jude EB
AUID- ORCID: 0000-0002-3186-4122
AD  - Diabetes Center, Tameside and Glossop Integrated Care NHS Foundation Trust, 
      Ashton Under Lyne, UK. Edward.jude@tgh.nhs.uk.
AD  - University of Manchester, Lancashire, UK. Edward.jude@tgh.nhs.uk.
LA  - eng
SI  - ClinicalTrials.gov/NCT03968198
SI  - ClinicalTrials.gov/NCT04466007
SI  - ClinicalTrials.gov/NCT04661644
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20230922
PL  - New Zealand
TA  - Mol Diagn Ther
JT  - Molecular diagnosis & therapy
JID - 101264260
SB  - IM
MH  - Humans
MH  - *Diabetic Foot/therapy
MH  - Amputation, Surgical
MH  - Ischemia/etiology/therapy
MH  - Cell- and Tissue-Based Therapy
MH  - Treatment Outcome
MH  - Risk Factors
MH  - Retrospective Studies
MH  - *Diabetes Mellitus
PMC - PMC10590286
COIS- Michal Dubsky, Jitka Husakova, Dominika Sojakova, Vladimira Fejfarova, and Edward 
      B. Jude declare that they have no conflicts of interest that might be relevant to 
      the contents of this article.
EDAT- 2023/09/23 11:41
MHDA- 2023/12/17 09:43
PMCR- 2023/09/22
CRDT- 2023/09/22 23:30
PHST- 2023/07/16 00:00 [accepted]
PHST- 2023/12/17 09:43 [medline]
PHST- 2023/09/23 11:41 [pubmed]
PHST- 2023/09/22 23:30 [entrez]
PHST- 2023/09/22 00:00 [pmc-release]
AID - 10.1007/s40291-023-00667-w [pii]
AID - 667 [pii]
AID - 10.1007/s40291-023-00667-w [doi]
PST - ppublish
SO  - Mol Diagn Ther. 2023 Nov;27(6):673-683. doi: 10.1007/s40291-023-00667-w. Epub 
      2023 Sep 22.